Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Approaches for developing novel microtubule targeting agents (MTAs) for therapeutic exploitation.

Krishnan A, Wilson J, Leung HY.

Curr Pharm Des. 2012;18(19):2804-10. Review.

PMID:
22390764
[PubMed - indexed for MEDLINE]
2.

New paradigms in microtubule-mediated endocrine signaling in prostate cancer.

Mistry SJ, Oh WK.

Mol Cancer Ther. 2013 May;12(5):555-66. doi: 10.1158/1535-7163.MCT-12-0871. Epub 2013 May 1. Review.

PMID:
23635655
[PubMed - indexed for MEDLINE]
Free Article
3.

Tubulins as therapeutic targets in cancer: from bench to bedside.

Katsetos CD, Dráber P.

Curr Pharm Des. 2012;18(19):2778-92. Review.

PMID:
22390762
[PubMed - indexed for MEDLINE]
4.

Update on tubulin-binding agents.

Attard G, Greystoke A, Kaye S, De Bono J.

Pathol Biol (Paris). 2006 Mar;54(2):72-84. Review.

PMID:
16545633
[PubMed - indexed for MEDLINE]
5.

Microtubules in apoptosis induction: are they necessary?

Estève MA, Carré M, Braguer D.

Curr Cancer Drug Targets. 2007 Dec;7(8):713-29. Review.

PMID:
18220532
[PubMed - indexed for MEDLINE]
6.

Microtubule alterations and resistance to tubulin-binding agents (review).

Drukman S, Kavallaris M.

Int J Oncol. 2002 Sep;21(3):621-8. Review.

PMID:
12168109
[PubMed - indexed for MEDLINE]
7.

How do microtubule-targeted drugs work? An overview.

Jordan MA, Kamath K.

Curr Cancer Drug Targets. 2007 Dec;7(8):730-42. Review.

PMID:
18220533
[PubMed - indexed for MEDLINE]
8.

Recent patents reveal microtubules as persistent promising target for novel drug development for cancers.

Bughani U, Li S, Joshi HC.

Recent Pat Antiinfect Drug Discov. 2009 Nov;4(3):164-82. Review.

PMID:
19673697
[PubMed - indexed for MEDLINE]
9.

Targeting microtubules for cancer chemotherapy.

Zhou J, Giannakakou P.

Curr Med Chem Anticancer Agents. 2005 Jan;5(1):65-71. Review.

PMID:
15720262
[PubMed - indexed for MEDLINE]
10.

A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.

Zhang J, Zhou J, Ren X, Diao Y, Li H, Jiang H, Ding K, Pei D.

Invest New Drugs. 2012 Apr;30(2):490-507. doi: 10.1007/s10637-010-9577-1. Epub 2010 Nov 16.

PMID:
21080210
[PubMed - indexed for MEDLINE]
11.

Microtubule-associated proteins as targets in cancer chemotherapy.

Bhat KM, Setaluri V.

Clin Cancer Res. 2007 May 15;13(10):2849-54. Review.

PMID:
17504982
[PubMed - indexed for MEDLINE]
Free Article
12.

Tubulin and microtubules as targets for anticancer drugs.

Hadfield JA, Ducki S, Hirst N, McGown AT.

Prog Cell Cycle Res. 2003;5:309-25. Review.

PMID:
14593726
[PubMed - indexed for MEDLINE]
13.

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.

Perez EA.

Mol Cancer Ther. 2009 Aug;8(8):2086-95. doi: 10.1158/1535-7163.MCT-09-0366. Epub 2009 Aug 11. Review. Erratum in: Mol Cancer Ther. 2012 Jun;11(6):1381.

PMID:
19671735
[PubMed - indexed for MEDLINE]
Free Article
14.

Microtubule targeting agents: from biophysics to proteomics.

Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, Lafitte D.

Cell Mol Life Sci. 2010 Apr;67(7):1089-104. doi: 10.1007/s00018-009-0245-6. Epub 2010 Jan 28. Review.

PMID:
20107862
[PubMed - indexed for MEDLINE]
15.

Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.

Lee JJ, Kelly WK.

Nat Clin Pract Oncol. 2009 Feb;6(2):85-92. doi: 10.1038/ncponc1281. Epub 2008 Dec 2. Review.

PMID:
19048010
[PubMed - indexed for MEDLINE]
16.

CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line.

Huang YT, Huang DM, Guh JH, Chen IL, Tzeng CC, Teng CM.

J Biol Chem. 2005 Jan 28;280(4):2771-9. Epub 2004 Nov 9.

PMID:
15536083
[PubMed - indexed for MEDLINE]
Free Article
17.

New tubulin targeting agents currently in clinical development.

Carlson RO.

Expert Opin Investig Drugs. 2008 May;17(5):707-22. doi: 10.1517/13543784.17.5.707 . Review.

PMID:
18447597
[PubMed - indexed for MEDLINE]
18.

Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.

Verrills NM, Kavallaris M.

Curr Pharm Des. 2005;11(13):1719-33. Review.

PMID:
15892670
[PubMed - indexed for MEDLINE]
19.

Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.

Gupta K, Bishop J, Peck A, Brown J, Wilson L, Panda D.

Biochemistry. 2004 Jun 1;43(21):6645-55.

PMID:
15157098
[PubMed - indexed for MEDLINE]
20.

Microtubule-targeted anticancer agents and apoptosis.

Bhalla KN.

Oncogene. 2003 Dec 8;22(56):9075-86. Review.

PMID:
14663486
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk